Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Combined With Cetuximab and mFOLFIRI in First-Line Recurrent or Metastatic Colorectal Cancer
NCT07874438Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in colorectal cancer (CRC), sponsored by Jiangsu Provincial People's Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07874438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07874438.